Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Ruby Khatun Khatun
    Ruby Khatun Khatun
      • Home
      • Ruby Khatun Khatun

      Articles By : Ruby Khatun Khatun

      Aurobindo to acquire Sandoz US dermatology, oral solids business for about Rs 6,470 crore CASH

      Aurobindo to acquire Sandoz US dermatology, oral solids business for about Rs 6,470 crore CASH

      Ruby Khatun Khatun7 Sept 2018 12:44 PM IST
      Overall the transaction will position Aurobindo as the 2nd largest dermatology player and the 2nd largest generics company in the US by prescriptions,...
      NCLT issues notices to Malvinder, Godhvani; directs status quo over RHC Holdings

      NCLT issues notices to Malvinder, Godhvani; directs status quo over RHC Holdings

      Ruby Khatun Khatun7 Sept 2018 10:30 AM IST
      New Delhi: The National Company Law Tribunal (NCLT) on Thursday issued notices to Malvinder Mohan Singh, ex-Religare chief Sunil Godhwani and others,...
      Insurance tactic drags down US drug prices in second quarter: analyst

      Insurance tactic drags down US drug prices in second quarter: analyst

      Ruby Khatun Khatun7 Sept 2018 9:45 AM IST
      NEW YORK: U.S. drug prices fell again in the second quarter, likely due to new tactic insurers are using to limit financial assistance drugmakers...
      Sanofi to pay more than 25 million dollar to resolve corruption charges: SEC

      Sanofi to pay more than 25 million dollar to resolve corruption charges: SEC

      Ruby Khatun Khatun7 Sept 2018 9:30 AM IST
      WASHINGTON: French pharmaceutical giant Sanofi will pay more than $25 million to settle charges that its Kazakhstan and the Middle East subsidiaries...
      Ranbaxy Fiasco:  Malvinder Singh told to pay 3.5 million Singapore dollars

      Ranbaxy Fiasco: Malvinder Singh told to pay 3.5 million Singapore dollars

      Ruby Khatun Khatun6 Sept 2018 1:19 PM IST
      New Delhi: The Delhi High Court on Wednesday directed former Ranbaxy Laboratories Ltd promoter Malvinder Singh to deposit with it 3.5 million...
      Family feud: Shivinder accuses Malvinder of forging wifes signature

      Family feud: Shivinder accuses Malvinder of forging wife's signature

      Ruby Khatun Khatun6 Sept 2018 12:14 PM IST
      New Delhi: Former Fortis Healthcare promoter Shivinder Mohan Singh has alleged that his elder brother Malvinder forged his wife's signature,...
      Zydus Cadila gets USFDA approval for antiviral drug

      Zydus Cadila gets USFDA approval for antiviral drug

      Ruby Khatun Khatun6 Sept 2018 10:44 AM IST
      New Delhi: Drug firm Zydus Cadila said it has received final approval from the US health regulator to market Acyclovir injection, used to treat...
      Immense scope for medical tourism between India, Netherlands: Ayush Minister

      Immense scope for medical tourism between India, Netherlands: Ayush Minister

      Ruby Khatun Khatun6 Sept 2018 10:00 AM IST
      The Hague: There is an immense scope for cooperation in medical tourism between India and the Netherlands, Union Minister of State for Ayush Shripad...
      ProQR drug for rare childhood blindness succeeds in early trial

      ProQR drug for rare childhood blindness succeeds in early trial

      Ruby Khatun Khatun6 Sept 2018 9:45 AM IST
      Dutch drug developer ProQR Therapeutics NV said its interim analysis showed that an early-stage trial of an experimental treatment for a rare form of...
      UK deal makes Novartis cancer cell therapy available to kids

      UK deal makes Novartis cancer cell therapy available to kids

      Ruby Khatun Khatun6 Sept 2018 9:30 AM IST
      LONDON: Health authorities in England have agreed with Swiss drugmaker Novartis to fast-track access to its expensive CAR-T cell therapy Kymriah and...
      JnJ Faulty Hip Implants: Another Expert panel formed to determine compensation to patients

      JnJ Faulty Hip Implants: Another Expert panel formed to determine compensation to patients

      Ruby Khatun Khatun5 Sept 2018 12:39 PM IST
      New Delhi: The Centre has constituted a five-member expert committee to determine the quantum of compensation to be given to patients who have...
      Former Fortis Healthcare promoter Shivinder Singh sues brother Malvinder, ends business ties

      Former Fortis Healthcare promoter Shivinder Singh sues brother Malvinder, ends business ties

      Ruby Khatun Khatun5 Sept 2018 11:15 AM IST
      New Delhi: Former Fortis Healthcare promoter Shivinder Singh said Tuesday he has moved the National Company Law Tribunal (NCLT) against elder brother...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok